BioSpace News Archive

Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.

SciSparc Ltd. announced today that it signed a merger agreement (the “Agreement”) with AutoMax Motors Ltd. (“AutoMax”), a leading vehicle importer company in Israel.

Macomics Ltd, a leader in macrophage drug discovery, has unveiled details of its lead programme, a first-in-class ligand independent-pan-LILRB monoclonal antibody for the treatment of cancer, having presented key data on MACO-355 at the American Association for Cancer Research Annual Meeting in San Diego1.

BrainStorm Cell Therapeutics Inc. announced that it received a notification letter on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market, indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550.

West Pharmaceutical Services, Inc. announced that it will release first-quarter financial results before the market opens on Thursday, April 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

FundaMental Pharma GmbH, a neuroscience company developing first-in-class small molecule inhibitors for the treatment of a range of neurodegenerative diseases, is pleased to announce the appointment of Dr. Dirk Beher as Chief Executive Officer and Executive Board member.

Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces it will be attending and presenting at the Bloom Burton & Co. Healthcare Investor Conference taking place at the Metro Toronto Convention Center, North Building, on April 16 and 17, 2024.

Arvinas, Inc. announced it has entered into an exclusive strategic license agreement with Novartis for the worldwide development and commercialization of ARV-766, Arvinas’ second generation PROTAC® androgen receptor degrader for patients with prostate cancer.

Agendia®, Inc. announced that the company’s 80-gene molecular subtyping assay, BluePrint®, is now included in the latest version of German Gynecological Oncology Group guidelines.

Gerresheimer, an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries, continued its profitable growth trajectory in the first quarter of 2024 with organic revenue growth of 2.8% and an organic increase in adjusted EBITDA of 5.9%.